Benefit of Carbohydrate Deficient Transferrin to Detect Chronic Alcohol

Status Completed

Clinical Trial Summary

Alcohol misuse affects 5 million people in France. Even though the elderly are also concerned by this pathology, there is not much information about chronic alcohol misuse of this population in particular.

Biological markers like gamma-glutamyltranspeptidase (GGT), mean corpuscular volume (MCV) and carbohydrate deficient transferrin (CDT) are usually used to detect alcohol abuse. As a biological marker of alcohol misuse, the specificity of the CDT is known to be superior to the GGT as well.

However, when it comes to the elderly, alcoholism diagnosis tools are based on research of younger populations.

This study aims to evaluate the benefit of the CDT to detect chronic alcohol use in the elderly.

Clinical Trial Description

Problematic alcohol misuse is frequent but tends to decrease with age. According to the French Alcohology Society, 10% of the adult population is alcohol abstinent and after 65 years old, they are 40% to abstain from alcohol.

On the other hand, the French Alcohology Society also reports that a regular or daily alcohol consumption for older people increases the risk of dependence on alcohol.

For the elderly, biological disorders can be related to polymedication or other conditions related to the aging process, making it difficult to diagnose alcoholism for aged people.

For the study, the three-item Alcohol Use Disorders Identification Test (AUDIT-C) will be submitted to :

- every patient admitted in the Hospital of Mulhouse (France) for at least a day in the Geriatrics Department

- every patient entering the General Practitioner Support Association of Alsace, France (translated in French as the "RAG").

When the score of the AUDIT-C reaches at least 1 point, the study will collect results of the GGT and MCV performed as routine practice and add the CDT in the blood tests. ;

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02822911
Study type	Interventional
Source	Groupe Hospitalier de la Region de Mulhouse et Sud Alsace
Contact
Status	Completed
Phase	N/A
Start date	March 2016
Completion date	October 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03165942` - Neuroendocrine Response to Oral Alcohol Administration	Phase 1
Recruiting	`NCT05343039` - Technology Enhanced Adolescent Mental Health (TEAM)	N/A
Active, not recruiting	`NCT04070521` - EEG Monitoring in the Emergency Department
Completed	`NCT03169244` - Buproprion for Binge Drinking	Phase 2
Recruiting	`NCT05246202` - Personalized Feedback Intervention for Latinx Drinkers With Anxiety	N/A
Completed	`NCT05036499` - PFI for Pain-Related Anxiety Among Hazardous Drinkers With Chronic Pain	N/A
Recruiting	`NCT04368416` - Anxiety/Depression, Sleep and Alcohol in Elderly Anxiety/Depression, Sleep Disturbances and Alcohol Use Disorder in Elderly With Cognitive Complaints
Not yet recruiting	`NCT04557631` - Evaluation of the Threshold for the Interpretation of the Results of a Method for the Blood Determination of Phosphatidyléthanol
Terminated	`NCT00890149` - Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults	Phase 2
Completed	`NCT02448134` - A Community-Based Strategy for Preventing Underage Drinking	N/A
Completed	`NCT02179749` - Mifepristone Treatment of Alcohol Use Disorder	Phase 2
Completed	`NCT02681406` - Smartphone Based Continuing Care for Alcohol	N/A
Withdrawn	`NCT01796158` - Pilot Test of Computerized MET to Reduce Adolescent Alcohol Use	N/A
Withdrawn	`NCT01847300` - cSBI-M for Young Military Personnel	N/A
Terminated	`NCT01408641` - Topiramate for Alcohol Use in Posttraumatic Stress Disorder	N/A
Withdrawn	`NCT01511679` - Brain-imaging and Adolescent Neuroscience Consortium	N/A
Completed	`NCT01553136` - Varenicline Treatment of Alcohol Dependence in Smokers	Phase 2
Withdrawn	`NCT01275391` - cSBIRT to Reduce Teen Tobacco, Alcohol and Drug Use	Phase 1/Phase 2
Active, not recruiting	`NCT01539525` - Screening to Augment Referral to Treatment- Project START	Phase 2
Completed	`NCT00907309` - Dental and Medical Office iMET to Reduce Teen Tobacco, Alcohol, and Drug Use	Phase 1/Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Benefit of Carbohydrate Deficient Transferrin to Detect Chronic Alcohol Abuse in the Elderly — Caesar

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms